Endothelium-Derived Hyperpolarizing Factor and Vascular Function by Ozkor, Muhiddin A. & Quyyumi, Arshed A.
SAGE-Hindawi Access to Research
Cardiology Research and Practice
Volume 2011, Article ID 156146, 12 pages
doi:10.4061/2011/156146
Review Article
Endothelium-DerivedHyperpolarizingFactor and
Vascular Function
Muhiddin A. Ozkor1 andArshedA.Quyyumi2
1The Heart Hospital, University College London, London WIG 8PH, UK
2Division of Cardiology, Department of Medicine, Emory University, 1364 Clifton Road NE, Suite 403C, Atlanta, GA 30322, USA
C o r r e s p o n d e n c es h o u l db ea d d r e s s e dt oA r s h e dA .Q u y y u m i ,aquyyum@emory.edu
Received 7 March 2011; Revised 27 May 2011; Accepted 27 May 2011
Academic Editor: Abarmard Maziar Zafari
Copyright © 2011 M. A. Ozkor and A. A. Quyyumi. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Endothelial function refers to a multitude of physiological processes that maintain healthy homeostasis of the vascular wall.
Exposure of the endothelium to cardiac risk factors results in endothelial dysfunction and is associated with an alteration in
the balance of vasoactive substances produced by endothelial cells. These include a reduction in nitric oxide (NO), an increase in
generation of potential vasoconstrictor substances and a potential compensatory increase in other mediators of vasodilation. The
latterhasbeensurmisedfromdatademonstratingpersistentendothelium-dependentvasodilatationdespitecompleteinhibitionof
NO and prostaglandins. This remaining non-NO, non-prostaglandin mediated endothelium-dependent vasodilator response has
been attributed to endothelium-derived hyperpolarizing factor/s (EDHF). Endothelial hyperpolarization is likely due to several
factors that appear to be site and species speciﬁc. Experimental studies suggest that the contribution of the EDHFs increase as
the vessel size decreases, with a predominance of EDHF activity in the resistance vessels, and a compensatory up-regulation of
hyperpolarizationinstatescharacterizedbyreducedNOavailability.Sinceendothelialdysfunctionisaprecursorforatherosclerosis
development and its magnitude is a reﬂection of future risk, then the mechanisms underlying endothelial dysfunction need to be
fully understood, so that adequate therapeutic interventions can be designed.
1.Introduction
Endothelial function refers to a multitude of physiological
processes of the vascular endothelium that maintain healthy
homeostasis of the vascular wall and may be used as a “bar-
ometer” of the injury/repair inﬂicted by multiple envi-
ronmental and genetic factors [1–3]. Vascular endothelial
dysfunction is associated with a reduction in nitric oxide
(NO) bioavailability, an increase in generation of potential
vasoconstrictorsubstancessuchassuperoxideanionsanden-
dothelin–1, and a potential compensatory increase in other
mediators of vasodilation. This remaining non-NO, non-
prostaglandin-mediated endothelium-dependent vasodila-
tion has been partly attributed to endothelium-derived hy-
perpolarizing factor/s (EDHF). Endothelial hyperpolariza-
tion is likely due to several factors that are site- and species-
speciﬁc, ultimately causing vascular smooth muscle hyper-
polarization and relaxation. Experimental studies suggest
that the contribution of EDHFs increase as the vessel size
decreases, with predominant EDHF activity in the resistance
vessels and a compensatory upregulation of EDHFs in states
characterized by reduced NO availability [4–12]. Whereas
prostacyclin and NO bioavailability have been extensively
investigated in the human circulation in vivo, little is known
about endothelial hyperpolarization.
2.Endothelium-DerivedHyperpolarizing
Factor (EDHF)
Potential EDHFs diﬀer by species and vascular bed, but
act by increasing potassium (K+) conductance resulting in
the subsequent propagation of depolarization of vascular
smooth muscle cells and relaxation [13–15]( Figure 1).
Acetylcholine causes hyperpolarization of vascular smooth
muscle in arteries with an intact endothelium but not in
its absence [16–19]. This hyperpolarization is mimicked by2 Cardiology Research and Practice
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Figure 1: Mechanisms for endothelial cell mediated relaxation. Agonist (bradykinin/acetylcholine/substance P) or shear stress increases the
activity of endothelial NO synthase (eNOS) and cyclooxygenase (COX), providing nitric oxide x(NO) and prostacyclin(PGI2)-mediated
dilation. There are multiple potential EDHF pathways. Increases in intracellular calcium activates phospholipase A2 (PLC) to produce
arachidonic acid. Its metabolism by cytochrome P450 2C (CYP4502c) generates eicosatrienoic acids (EETs) that can stimulate calcium
dependent potassium (KCa
+) channels in endothelial and smooth muscle cells. EETs may also directly activate gap junctions (Gap). EETs
may also act in an autocrine manner on endothelial cells by activating transient receptor potential (TRP) V4 channels, which promote
Calcium (Ca++) inﬂux further increasing the calcium concentration and activating KCa
+ channels to cause hyperpolarization and release
of K+ ions into the subendothelial space. The increase in potassium in the interstitium may activate KCa
+ channels, inwardly rectifying
potassium channels (KIR
+), or the Na+-K+ pump on smooth muscle cells and cause hyperpolarization. Smooth muscle hyperpolarization in
turn results in relaxation by closing voltage-gated channels leading to a fall in Ca++ concentration and subsequent vasodilation. The action
of eNOS (with cofactor tetrahydrobiopterin [BH4]) and oxidases on oxygen (O2) produces the reactive oxygen species superoxide (.O2−).
Hydrogen peroxide (H2O2) generated by dismutation of superoxide anions by superoxide dismutase(SOD) can also causehyperpolarization
by activating endothelial and smooth muscle KCa
+ channels or by gap junctions. Adenylyl cyclase: AC; cyclic Adenosine monophosphate:
cAMP; cyclic guanosine monophosphate: cGMP; soluble guanylyl cyclase: sGC; prostacyclin receptor, IP.
certain K+ channel agonists and is unaﬀected by inhibitors
of nitric oxide synthase or cyclooxygenase and has been
attributed to release of EDHF/s. EDHFs appear to open
smooth muscle cell K+ channels, allowing K+ eﬄux along
its chemical gradient resulting in membrane hyperpolariza-
tion. Thus, EDHF activity may be deﬁned functionally as
agonist-induced, endothelium-dependent relaxation that is
not blocked by inhibitors of NO synthase or cyclooxygenase
but can be inhibited, at least in part, by K+ channel blockers.
2.1. Potassium (KCa
+) Channel Activation (Figure 1)
2.1.1. Calcium-Activated Potassium (KCa
+) Channels. Ago-
nists such as bradykinin stimulate endothelial G protein-
coupled receptors provoking an increase in intracellular cal-
cium [Ca2+]i in the endothelial cell [20, 21]. Endothelium-
dependent hyperpolarization of smooth muscle cells results
from the opening of K+ channels in the smooth muscle
plasmalemma and is abolished by K+ concentrations higher
than 25mM [22]. Agonists that produce hyperpolarization
alsostimulateeﬄuxofK+ [17,23].However,thereareseveral
smoothmuscleK+ channels;endothelium-dependent hyper-
polarization is not prevented by glibenclamide, an inhibitor
of ATP-dependent K+ channels (KATP
+), or inhibitors of
inwardly rectifying potassium channels (KIR
+)[ 24]. How-
ever, both barium chloride (<100μmol/L) and ouabain
(2.7nmol/min), inhibitors of KIR
+ channels, reduced resting
ﬂow in healthy subjects, an eﬀect that was lower in obesity,
eventhoughthesearenotendothelium-dependentresponses
[25].
The hallmark of the EDHF-mediated responses is its ab-
olition by the combination of apamin (a speciﬁc inhibi-
tor of KCa
+ channels of small conductance (SKCa
+ channels))
plus charybdotoxin (a nonselective inhibitor of large-con-
ductance (BKCa
+) and intermediate-conductance (IKCa
+)
channels),andofsomevoltage-dependentK+(KV
+)channels
[26–28]. This toxin combination targets KCa
+ channels on
endothelial cells rather than K+ channels located on smoothCardiology Research and Practice 3
musclecells.Increasingintracellularfreecalciuminendothe-
lial cells opens KCa
+ channels allowing eﬄux and accumula-
tion of K+ into the myoendothelial space. This triggers sev-
eral processes that explain the EDHF phenomena; including
(1)synthesisofcytochromethatP450(CYP450)metabolites,
a family of epoxides, (2) transmission of endothelial cell
hyperpolarization to the vascular smooth muscle via gap
junctions, and (3) K+ released from the endothelial cells via
KCa
+ channels induces smooth muscle hyperpolarization by
activating KCa
+ channels and/or Na+-K+-ATPase on vascular
smooth muscle cells.
Studyofgastroepiploicconductancearteriesandmicrov-
essels revealed that the contribution of EDHF to endothe-
lium-dependent relaxations is signiﬁcantly larger in human
microvessels than in large arteries, that EDHF-mediated
relaxations are mediated via activation of K+ channels,
and that risk factors, particularly hypercholesterolemia and
aging, were associated with impaired EDHF-mediated dila-
tion [4]. Convincing evidence has been presented to suggest
that a CYP450-dependent EDHF plays a signiﬁcant role in
the regulation of coronary arteriolar tone by KCa
+ channel
activation and smooth muscle hyperpolarization [8, 29].
Thus, L-NG-nitro arginine/indomethacin-insensitive com-
ponent of acetylcholine-mediated relaxation was sensitive to
25mmol/L K+, but not to glibenclamide, a KATP channel
inhibitor. Importantly, relaxation in human subcutaneous
resistance arteries was abolished by a combination of
charybdotoxin and apamin indicating the crucial role for
endothelial KCa
+ channel activation [7].
Human studies have used tetraethylammonium chloride
(TEA) to investigate the role of large KCa
+ channel activation
onforearmbloodﬂowandonthevasculareﬀectsofbradyki-
nin. TEA selectively blocks KCa
+ channels in arterial smooth
muscle cells at concentrations of >1mmol/L [29]. At these
doses,TEAdecreasedrestingforearmbloodﬂowby23%and
radial artery diameter by 5%, and it also inhibits bradykinin-
and substance P-induced, but not acetylcholine-mediated
vasodilation afterinhibition of NO and prostaglandins in the
forearm microcirculation [30–32]. Moreover, resting radial
arterial blood ﬂow and diameter were reduced only with
combined blockade of NO synthesis and KCa
+ channels
but not with either blockade individually, suggesting an
important interaction between these two vasodilator systems
[31]. These observations demonstrate the contribution of
bothNOandKCa
+ channelactivationtorestingconductance
artery and microvascular tone in the healthy human forearm
circulation.
2.2.EpoxyeicosatrienoicAcids(EETS)(Figure 1). Epoxyeicos-
atrienoic acids (EETs) are arachidonic acid derived products
of cytochrome P450 (CYP450) epoxygenases [33]. CYP450
enzymes are membrane-bound, heme-containing terminal
oxidases in a multienzyme system. The arachidonic acid
metabolizing CYP450 enzymes with prominent roles in
vascular regulation are the epoxygenases of the CYP 2 gene
family (e.g., CYP 2B, 2C8, 2C9, 2C10, and 2J2 in humans)
that generate a series of region-speciﬁc and stereo-speciﬁc
epoxides (5,6-, 8,9-, 11,12-, and 14,15-EETs), and the arachi-
donic acid v-hydroxylases belonging to the CYP 4A family
which form hydroxyeicosatetraenoic acids (HETEs) which
can demonstrate organ speciﬁc opposed actions [34].
Evidence in favor of EDHF being a short-lived metabo-
lite of the cytochrome P450 epoxygenase pathway has been
obtained using bovine [35, 36], porcine [36, 37], canine
[38, 39], murine [40, 41], and human coronary arteries
[8, 9, 29, 42–45]. EDHF-mediated responses are blocked
by nonspeciﬁc CYP450 inhibitors such as miconazole, 17-
octadecynoicacid,andmoreselectiveepoxygenaseinhibitors
[6-(2-proparglyloxyphenyl) hexanoic acid and N-methyl-
sulphonyl-6-(2-propargyloxyphenyl) hexanamide] [46–48].
RT-PCR, Western blotting, and immunoﬂuorescence tech-
niques have demonstrated that native coronary endothe-
lial cells express CYP epoxygenases, including CYP 2C8,
CYP 2C9, and CYP 2J2 [49–52]. EET-induced activation
of KCa
+ channels appears to be mediated by a cascade
of intracellular events involving the ADP ribosylation of
cellular proteins including anti-G(S)alpha antibody [53, 54]
ultimatelyhyperpolarizingsmoothmusclecellsbyincreasing
the open-state probability of KCa
+ channels [35, 41, 50, 55].
In porcine coronary arteries, a CYP450-derived epoxide,
namely11,12-epoxyeicosatrienoicacid(11,12-EET)hasbeen
shown to possess EDHF properties because (1) both 11,12-
EET and bradykinin elicit hyperpolarization; (2) endothelial
cells, but not smooth muscle cells, expressed mRNA and
proteinfortheepoxygenaseenzymeoftheCYP2Cfamilyand
released 11,12-EET; (3) induction of CYP2C8 or CYP2C34
increasedepoxygenaseexpression, whichwasassociatedwith
increased release of 11, 12-EET, and enhanced relaxation and
hyperpolarizationinresponsetobradykinin;(4)anantisense
oligonucleotide directed at the endothelial epoxygenase re-
duced both CYP2C mRNA and protein expression and the
capacity to generate 11,12-EET, concomitantly with a re-
duction in the vasorelaxant and hyperpolarizing response to
bradykinin [50]. The ﬁnding that sulfaphenazole, a selective
inhibitor of CYP 2C9 [56, 57], inhibits EDHF-mediated
responses [50] and potentiates non-NO-mediated relaxation
in the porcine coronary artery [33] suggests that the CYP
isoform required for the generation of EDHF is a porcine
equivalent of CYP 2C9 [58]. Further, there is evidence
in some species that CYP450-derived epoxides stimulate
Na+/K+ ATPase [59]. These data strongly suggest that the ac-
tivation of a cytochrome P450 epoxygenase is a prerequisite
for the generation of EDHF-mediated relaxation in certain
species.
Other intracellular second messenger roles of EETs may
be equally as important in the control of vascular homeosta-
sis. EETs (in particular 11,12- and 14,15-EET) activate sev-
eral intracellular protein kinases including tyrosine kinases,
the p38 MAP kinase, and extracellular-regulated protein
kinases 1 and 2 (Erk1/2) and increase the proliferation of
various cell types, including vascular smooth muscle cells
and endothelial cells [33, 60, 61].
In isolated human coronary arterioles, CYP450-depend-
ent hyperpolarization plays a signiﬁcant role in the regula-
tion of smooth muscle tone via activation of KCa
+ channels
[8, 29]. Human coronary arteriolar endothelium-dependent
hyperpolarization in response to arachidonic acid is much
more dependent on metabolism by CYP450 than by4 Cardiology Research and Practice
cyclooxygenase or lipoxygenase or activation of NO synthase
[8, 62]. The predominant EET synthesized by arteries is
11,12-EET, and its speciﬁc inhibition by chemically dis-
tinct CYP450 inhibitors impairs EDHF relaxation. 11,12-
EET activates large-conductance KCa
+ channel current and
hyperpolarizes arterial smooth muscle. Large-conductance
KCa
+ channels and CYP450-2C mRNA and proteins are less
abundant in arteries than saphenous veins explaining the
lack of EDHF activity of veins. Large-conductance KCa
+
channels are primarily present in vascular smooth muscle,
whereas the CYP450-2C enzyme is present in both the
endothelium and smooth muscle cells. Thus, in human in-
ternal mammary arteries, EDHF appears to be 11,12-EET,
produced by an EDHF synthase CYP450-2C and accounts
for 40% of net endothelial relaxation by stimulating large-
conductance KCa
+ channels [6].
T h er o l eo fE E T sa sp o t e n t i a lE D H F sc a nb es t u d i e d
using azoles such as miconazole that selectively inhibit
epoxidation (EET generation) of arachidonic acid and have
beendemonstratedtobepartlyresponsibleforendothelium-
dependent vasodilation in the human microcirculation [9,
31,63].In vivo studieshavedemonstratedCYP450inhibition
does not alter conductance vessel diameter or resting blood
ﬂow[31,63,64],butafterinhibition ofNOandprostacyclin,
inhibition of EET synthesis further decreases radial arterial
blood ﬂow and diameter [31]. Thus, although it appears
that under resting conditions in the healthy human forearm,
conductance and resistance vessel tone is not modulated
by tonic activity of CYP450-derived epoxides, their role
becomes evident after inhibition of NO and prostacyclin
synthesis, illustrating the potential compensatory role of
EETs on maintenance of basal tone when NO availability is
diminished.
In recent studies, we have addressed previous con-
troversies regarding the contribution of EDHF to resting
vasodilator tone. In the largest cohort studied to date, an
important contribution of EDHF, via activation of KCa
+
channels, to resting microvascular dilator tone in the human
forearm in vivo has been demonstrated [65]. For the ﬁrst
time, we have also demonstrated that cytochrome P450-
derived epoxyeicosatrienoic acids also contribute to resting
vasodilator tone in the healthy microcirculation with the use
of ﬂuconazole to block their action. We found a relatively
greater contribution of NO compared to EDHF in the main-
tenance of resting vasodilator tone in the healthy human
forearm microvasculature. The contribution of these two
endogenous vasodilators to resting tone diﬀered in subjects
exposed to risk factors for atherosclerosis, in whom the
vasculature is characterized by decreased NO bioavailability.
We found preserved contribution of EDHF that appears to
contribute equally as much as NO to resting vasodilator
tone in subjects with risk factors. In the presence of NO
blockade with L-NMMA, epoxyeicosatrienoic acid-mediated
microvascular vasodilation also appeared to be upregulated
in healthy subjects [65]. This indicates potential cross-talk
between the NO and EET pathways, such that EET activity
is upregulated in the setting of NO deﬁciency which may
be demonstrated by blocking NO synthesis in the healthy
circulation. Interestingly, in the risk factor group, there
was a similar contribution of EETs to resting tone in the
presence and absence of NO blockade. Such compensation
may be crucial in maintaining normal resting blood ﬂow in
nonhypertensive patients with risk factors.
Finally, by conducting experiments using single and
combinedblockade,wealsodemonstratedthatKCa
+ channel
activation contributes to microvascular dilator tone even
after inhibition of epoxyeicosatrienoic acids. This indicates
that sources other than epoxyeicosatrienoic acids contribute
to hyperpolarization of the resting human forearm micro-
circulation. Potential candidates which have been investi-
gated in experimental studies, include hydrogen peroxide,
potassium ions, and gap junctions. These alternate pathways
warrant further investigation in vivo in humans.
2.3. Hydrogen Peroxide. Hydrogen peroxide also activates
calcium-dependent potassium channels and remains a con-
tender as an EDHF [66]( Figure 1). Reactive oxygen species
can increase K+ channel activity and hyperpolarize smooth
muscle [67, 68], and hydrogen peroxide may function
as an EDHF [69]. Rubanyi and Vanhoutte reported that
superoxide attenuates endothelium-dependent relaxations
and that hydrogen peroxide causes endothelium-dependent
and -independent relaxations [70]. Matoba et al. utilized
catalase, an endogenous peroxidase to show inhibition of
EDHF-mediated, endothelium-dependent relaxations and
hyperpolarizations, resistant to indomethacin or N(omega)-
nitro-l-arginine [71]. These ﬁndings have been conﬁrmed
in piglet pial arteries, canine subepicardial coronary arteries
and arterioles, and during ﬂow-induced vasodilation in
human mesenteric arteries and coronary microvessels [66,
72–74].
Vascular endothelial cells have a capacity to produce su-
peroxide and hydrogen peroxide from several intracellu-
lar sources, including endothelial NO synthase, cycloox-
ygenases, lipoxygenases, cytochrome P-450 epoxygenases,
NAD(P)H oxidases, and xanthine oxidase [71, 75–78]. Flow-
mediateddilationinvolvesgenerationofsuperoxideoriginat-
ingfrommitochondriaandshearstresselicitsluminalrelease
of mitochondrial ubisemiquinone, a source for generating
superoxide and hydrogen peroxide via metabolic processes
occurring between complex I and complex III of the electron
transport chain [79]. Although reactive oxygen species ap-
pear to ﬁt the proﬁle of EDHF, their physiologic role remains
a subject of debate particularly in some human arteries
becauseinhumanradialandinternalmammaryarteries,nei-
ther catalase nor superoxide dismutase inhibited relaxations
to carbachol [80, 81].
Hydrogen peroxide also mediates hyperpolarization via
activationofendothelialK+ channels,however,manyspecies
variations exist in the type of K+ channels that are activated
[67, 68, 72, 73, 82–84]. Importantly, in human coronary
microvessels, K+
Ca channels sensitive to charybdotoxin plus
apamin appear to mediate hyperpolarization [73, 85]. In
mouse mesenteric arteries, the inhibitory eﬀect of catalase
was unmasked by the inhibition of NO production, and vice
versa, suggesting that NO and EDHF (hydrogen peroxide)
compensate for each other [71, 86–89]. In canine subep-
icardial coronary arteries and arterioles, the response toCardiology Research and Practice 5
acetylcholine and hypoxia was inhibited by L-NMMA pri-
marily in subepicardial coronary arteries, whereas combined
infusion of L-NMMA plus catalase or tetraethylammonium
attenuated the vasodilator responses of coronary arteries of
both sizes, demonstrating the predominance of hydrogen
peroxide-mediated hyperpolarization in microvessels [74].
2.4. Gap Junctions. The EDHF phenomenon may be further
explained by the transmission of endothelial cell hyperpo-
larization to the vascular smooth muscle via gap junctions
[90–92]. These are myoendothelial and heterocellular. They
couple endothelial cells to other endothelial cells and to
smooth muscle cells, providing a low-resistance electrical
pathway between the cell layers. Gap junctions are formed by
the docking of two connexons present in adjacent cells that
creates an aqueous pore permitting the transfer of ions and
electrical continuity that establishes a uniform membrane
potential across cells [93, 94]. Their number increases with
diminution in the size of the artery [95], paralleling the
importance of EDHF to vessel size with a greater inﬂuence
in the resistance than in the conductance vessels [96].
Investigation of gap junctions as other potential EDHF
mechanisms has been limited in man due to the lack of
speciﬁc pharmacological agents. Rotigaptide, that enhances
communication via the connexin 43 gap junction subunit,
had no eﬀect on basal vascular tone endothelium-dependent
(bradykinin), -independent vasodilation, or t-PA release in
the forearm arterial circulation of healthy men [97].
2.5. Potassium (K+). Am o d e r a t ei n c r e a s ei nt h em y o e n -
dothelial K+ concentration can in some species [98] induce
hyperpolarization of vascular smooth muscle cells by acti-
vating the inwardly rectifying K+ channels and the Na+/K +
ATPase [24, 99, 100]. However, it is unlikely that K+ per se is
EDHF.
3. InteractionsbetweenEDHF,
NitricOxide, andProstacyclin
The three main mediators of endothelial vasodilator func-
tion, NO, prostacyclin, and EDHF appear not to be mutually
exclusive and act synergistically in a complex manner to
maintain the health of the vasculature (Figure 1). In conduit
arteries,NOisthepredominantendothelium-derivedvasod-
ilator but has relatively less prominent contribution in the
resistance vessels of the microcirculation where EDHF ap-
pears to predominate [96]. NO may tonically inhibit EDHF
responses as some studies could only demonstrate EDHF
responses once NO production had been inhibited [44].
4.EDHFandDisease
Experimental evidence indicates that a shift away from NO-
mediated endothelium-dependent relaxation toward EDHF-
dependent relaxation occurs in disease states [101, 102]. Al-
teration of EDHF-mediated responses has been reported
with aging, hypertension, atherosclerosis, hypercholestero-
lemia, heart failure, angioplasty, eclampsia, diabetes, and
sepsis. Depending on the vascular bed, this may either con-
tribute to endothelial dysfunction or compensate for the loss
of NO bioavailability [103–105]. In the human forearm of
hypertensive subjects, Taddei and others demonstrated that
endothelium-dependent vasodilation is maintained despite
decreased NO bioavailability because of the compensatory
increased activity of EDHF [25, 104, 105]. Hypercholes-
terolemia is generally associated with preserved EDHF
responses where its enhanced activity may compensate for
the decrease in NO-mediated relaxation [106–108]. En-do-
thelium-dependent hyperpolarization appears to be inhib-
ited in isolated gastroepiploic arteries from atherosclerotic
patients, an eﬀect that may be secondary to the duration
of hypercholesterolemic injury [4]. In contrast, EDHF-me-
diated responses are depressed in some models of type I and
type II diabetes with the exception of murine models [109].
In the healthy forearm microcirculation, we demon-
strated that bradykinin-stimulated vasodilation is in part
mediated by activation of KCa
+ channels and that the magni-
tude of contribution of NO was less than the contribution of
KCa
+ channel activation [65]. Importantly, we found no con-
tribution of KCa
+ channel activation to acetylcholine-stim-
ulated vasodilation in healthy subjects, either in the presence
or absence of NO-blockade. Thus, acetylcholine predomi-
nantly stimulates the release of NO and no EDHF, whereas
bradykininstimulatesreleaseofbothEDHFandNO.Wealso
demonstrated a similar vcontribution of NO and EDHF to
bradykinin-mediated vasodilation in both groups. In con-
trast to eﬀects of bradykinin, forearm blood ﬂow response
to acetylcholine was diminished in hypercholesterolemic
subjects when compared to healthy subjects. Moreover, in
hypercholesterolemia,weobservedasigniﬁcantcontribution
of KCa
+ channel activation and a lower NO release with
acetylcholine that was distinctly diﬀerent compared to the
healthy circulation. Thus, while in health NO is the predom-
inant contributor, in hypercholesterolemia, both NO and
KCa
+ channel activation contribute equally to acetylcholine-
mediated microcirculatory vasodilation [65].
Evidence suggests that CYP expression [110–112]a n d
EET generation are increased in hypertension [113, 114],
duringsaltloading[115],andinhypercholesterolemia[116].
Members of the CYP 2C family are inhibited by NO, a phe-
nomenon that may explain why EDHF-mediated responses
are barely detectable in the absence of the combined inhibi-
tion of NO synthases and cyclooxygenase in normal vessels.
Thus the EET/EDHF pathway may be of less importance in
healthy vessels and of greater signiﬁcance in disease states
where NO activity is impaired [58]. A similar phenomenon
has been described for bradykinin-induced changes in
forearm blood ﬂow in essential hypertensive patients [25]
and in arterioles removed from patients with coronary artery
disease, where vasodilatation is mediated entirely by a mech-
anism sensitive to both CYP and KCa
+ channel inhibitors [9].
Such ﬁndings indicate that in the absence of NO, vascular
tone can be regulated by an EDHF-like mechanism. Thus,
whether EDHF plays a causal or compensatory role in the
endothelial dysfunction in the human circulation remains to
be elucidated.6 Cardiology Research and Practice
Table 1:PharmacologicalinhibitorsofEDHF.PharmacologicalagentsusedaspotentialinhibitorsofEDHFandtheirtargetsandlimitations
(modiﬁed from Torondel et al. [117]).
Pharmacological inhibitors Targets Comments
Apamin SKCa
+ Highly speciﬁc
Charybdotoxin IKCa
+-BKCa
+ Can inhibit some Kv channels
Iberiotoxin BKCa
+ Highly speciﬁc
Tetraethylammonium SKCa
+-IKCa
+-BKCa
+ Inhibit other K+ channels at >10−2)m
Tetraethybutylammonium SKCa
+-IKCa
+-BKCa
+ Inhibit other K+ channels at >10−2 m
BaCl2 KIR
+ —
Ouabain Na+/K+ ATPase Can aﬀect gap junction activity at >10−4 m
KCL K+ currents Dilates at >10−2 m through KIR
+ and Na+/K+ ATPase
activation
18 α-glycyrrhetic acid Gap junctions Possesses nonjunctional eﬀects on membrane currents
Connexin mimetic peptides Gap junctions Highly speciﬁc
Catalase Hydrogen peroxide —
17-octadecenoic acid CYP Inhibits the synthesis of the vasoconstrictor 20-HETE
Clotrimazole CYP Can inhibit K+ channels
Miconazole CYP Can inhibit K+ channels
Sulphaphenazole CYP epoxygenase Highly speciﬁc of CYP 2C9
Fluconazole CYP epoxygenase Can inhibit other CYP isoforms at >10−4 m
MSPPOH EETs synthesis inhibitor Highly speciﬁc
14,15-EEZE EETs antagonist Inhibits the vasodilator action of all EETs regioisomers
K+: potassium, SKCa
+: small calcium-dependent potassium channels, IKCa
+: intermediate calcium-dependent potassium channels, BKCa
+:l a r g ec a l c i u m -
dependent potassium channels, Kv: voltage dependent potassium channels, KIR
+: inwardly rectifying potassium channels, BaCl2 barium chloride, KCL:
potassium chloride, CYP: cytochrome, 20-HETE: 20-hydroxyeicosatetraenoic acids, MSPPOH: N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide,
EETs: epoxyeicosatrienoic acids, and 14,15-EEZE: 14,15-Epoxyeicosa-5(Z)-enoic Acid.
5. Summary
Absence of consensus regarding the precise identity of
EDHFs and a consequent lack of speciﬁc inhibitors has long
hampered clinical translation of this phenomenon (Table 1).
Recently, with improved understanding of the major signal-
ing mechanisms underlying vascular hyperpolarization, the
role of EDHF in the human circulation in vivo has begun to
be dissected, but experimental pitfalls remain. These include
the often nonspeciﬁc nature of the antagonists used, the
concentrations and duration of action of these blockers are
variable, and complete blockade cannot be achieved in vivo,
even with high doses, because of the competitive nature of
the antagonism. Nevertheless, an impressive body of knowl-
edge has already emerged regarding the role of EDHF in the
human circulation (Table 2).
Apart from its contribution to normal vascular physiol-
ogy,theaccentuatedroleofEDHFindiseasedstatesisworthy
offurtherinvestigationbecauseCYP-450expressionandEET
generation are increased in hypertension, during salt load-
ing and in hypercholesterolemia. Vasodilation in essential
hypertension[25],andinatheroscleroticcoronaryarterioles,
is largely secondary to CYP and KCa
+ channel stimulation.
There are also potential implications regarding disease sus-
ceptibility, with some polymorphisms within CYP epoxyge-
nases being associated with an enhanced risk of developing
coronary artery disease and hypertension [14]. What may
ultimately be of even greater interest is development of
speciﬁc agents targeting EDHF synthesis, understanding of
other biological eﬀects of EETs such as angiogenesis and
modulation of cell growth, and their potential role in human
disease [14].
6. Implications
Conventionally, endothelial dysfunction is characterized as
a deﬁciency of NO activity, often secondary to exposure to
cardiovascular risk factors. This leads to abnormalities in
vasodilation and hence blood ﬂow delivery. Because of the
known protective role of NO on the vessel wall that impedes
thrombosis and atherosclerosis, several strategies have been
appliedtoimproveNOavailability/activity.Althoughreplac-
ing NO pharmacologically with NO donors is beneﬁcial
for symptomatic relief from coronary vasodilation, there
appears to be no antiatherosclerotic eﬀect of NO donors.
Improving endothelial NO bioavailability with statins and
angiotensinantagonistshasneverthelessproventobecardio-
protective. What remains unknown is (a) whether enhancing
EDHF in conditions with impaired NO activity would also
be of therapeutic value, (b) whether agents that improve
endothelial dysfunction (acetylcholine responses) such as
statins and angiotensin antagonists, also enhance EDHF bi-
oactivity, and (c) whether tissue plasminogen activator
release is EDHF-dependent in health and disease. Indeed
hypertension is associated with elevated epoxide hydrolase
expression [128, 129], angiotensin II increases the expressionCardiology Research and Practice 7
Table 2: Human vascular territories with characterized EDHF activity.
Vascular territory EDHF Pharmacological agents used
Preclinical studies
Coronary arterioles
[8, 9, 29, 73, 118] H2O2,K Ca
+ channels, CYP450 metabolites
Catalase, KCl, charybdotoxin + Apamin,
polyethylene glycol catalase, KCl,
charybdotoxin, 7-octadecynoic acid
Internal Mammary artery [6, 62] 11,12-EET
17-octadecynoic acid,
N-methylsulfonyl-6-(2-
propargyloxyphenyl)hexanamide4,15-
epoxyeicosa-5(Z)-enoic
acid
Gastroepiploic arteries [4]K Ca
+ channels KCl
Mesenteric artery [66, 119] H2O2, Gap junctions, superoxide dismutase,
H2O2
Catalase, 18 alpha-glycyrrhetinic acid,
Tiron (cell-permeable SOD-mimetic),
catalase
Renal artery [10]K +,K Ca
+ channels KCl, charybdotoxin, and apamin
Subcutaneous resistance arteries [7] CYP450 metabolites, KCa
+ channels Ketoconazole
Subcutaneous resistance arteries
[120] (subcutaneous fat biopsies of
healthy pregnant women)
Connexin 43 Gap junctions. Connexin mimetic peptides
Visceral fat arterioles H2O2 Polyethylene glycol catalase
Umbilical vein endothelial cells
[85, 121] SKCa
+ channels, IKCa
+channels, H2O2
Apamin and
charybdotoxin/triarylmethane-34
Thyroid arteries [122]K Ca
+ channels, KIR
+ channels, Na+/K+ ATPase Iberiotoxin, charybdotoxin, apamin
glibenclamide, and barium
Clinical studies
Forearm microvasculature [63] CYP450 metabolites KCL, miconazole
Forearm microvasculature
[30, 32, 123] KCa
+ channels TEA
Forearm microvasculature [124] C-type natriuretic peptide C-type natriuretic peptide, TEA
Forearm microvasculature [104]
(hypertensive patients) CYP450 2C9 Sulfaphenazole
Forearm conductance vessel
[31, 125, 126] CYP 2C9 metabolites, KCa
+ channels Sulfaphenazole, TEA, ﬂuconazole
Thigh skeletal muscle vessels [127] CYP450 2C9 Sulfaphenazole
H2O2:H ydrogenP ero xide,K +:potassium,SKCa
+:smallcalcium-dependentpotassiumchannels,IKCa
+:intermediatecalcium-dependentpotassiumchannels,
KIR
+: inwardly rectifying potassium channels, KCL: potassium chloride, CYP: cytochrome, and EETs: epoxyeicosatrienoic acids.
of the epoxide hydrolase [130], and epoxide hydrolase in-
hibitors are eﬀective in reversing the hypertensive eﬀects
of angiotensin II [128]. Thus, epoxide hydrolase inhibitors
that increase epoxide levels and hence aid hyperpolarization
need to be further investigated in subjects with endothelial
dysfunction.
Experimental studies indicate that cytochrome P450 ex-
pression and EET generation are increased in hypertension
[104, 113], in hypercholesterolemia [116], and in athero-
sclerotic coronary arterioles [50, 64, 75]. Moreover, poly-
morphisms in the cytochrome P450 epoxygenase genes are
associated with increased risk of coronary artery disease and
hypertension [131, 132]. Thus, understanding the patho-
physiology of endothelial dysfunction beyond NO, and in
particular with respect to EDHF in these disease states, could
be crucial in understanding both the pathophysiology of
atherosclerosis and developing novel therapies.
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